Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Enterprise Value (2019 - 2025)

Avidity Biosciences' Enterprise Value history spans 7 years, with the latest figure at -$1.7 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 12.05% year-over-year to -$1.7 billion; the TTM value through Dec 2025 reached -$1.7 billion, down 12.05%, while the annual FY2025 figure was -$1.7 billion, 12.05% down from the prior year.
  • Enterprise Value reached -$1.7 billion in Q4 2025 per RNA's latest filing, up from -$1.9 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$279.5 million in Q2 2021 to a low of -$1.9 billion in Q3 2025.
  • Average Enterprise Value over 5 years is -$845.9 million, with a median of -$590.8 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: grew 20.71% in 2021, then tumbled 192.78% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$405.5 million in 2021, then plummeted by 50.59% to -$610.7 million in 2022, then grew by 2.52% to -$595.4 million in 2023, then crashed by 152.2% to -$1.5 billion in 2024, then fell by 12.05% to -$1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Enterprise Value are -$1.7 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$1.2 billion (Q2 2025).